Nothing Special   »   [go: up one dir, main page]

DK0946512T3 - 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer - Google Patents

6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer

Info

Publication number
DK0946512T3
DK0946512T3 DK97910587T DK97910587T DK0946512T3 DK 0946512 T3 DK0946512 T3 DK 0946512T3 DK 97910587 T DK97910587 T DK 97910587T DK 97910587 T DK97910587 T DK 97910587T DK 0946512 T3 DK0946512 T3 DK 0946512T3
Authority
DK
Denmark
Prior art keywords
phenylpyridyl
amine derivatives
derivatives useful
nos inhibitors
inhibitors
Prior art date
Application number
DK97910587T
Other languages
English (en)
Inventor
John Adams Lowe Iii
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0946512T3 publication Critical patent/DK0946512T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK97910587T 1996-12-06 1997-11-17 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer DK0946512T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3279396P 1996-12-06 1996-12-06
PCT/IB1997/001446 WO1998024766A1 (en) 1996-12-06 1997-11-17 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors

Publications (1)

Publication Number Publication Date
DK0946512T3 true DK0946512T3 (da) 2004-01-12

Family

ID=21866837

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97910587T DK0946512T3 (da) 1996-12-06 1997-11-17 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer

Country Status (42)

Country Link
US (3) US6235750B1 (da)
EP (1) EP0946512B1 (da)
JP (2) JP3604399B2 (da)
KR (1) KR100360633B1 (da)
CN (1) CN1117077C (da)
AP (1) AP848A (da)
AR (1) AR010331A1 (da)
AT (1) ATE251612T1 (da)
AU (2) AU4791797A (da)
BG (1) BG103540A (da)
BR (1) BR9714381A (da)
CA (1) CA2273479C (da)
CZ (1) CZ293863B6 (da)
DE (1) DE69725465T2 (da)
DK (1) DK0946512T3 (da)
DZ (1) DZ2361A1 (da)
EA (1) EA002907B1 (da)
ES (1) ES2206691T3 (da)
HN (2) HN1997000027A (da)
HR (1) HRP970664A2 (da)
HU (1) HUP0001848A3 (da)
ID (1) ID19056A (da)
IL (1) IL130111A0 (da)
IS (1) IS5053A (da)
MA (1) MA26453A1 (da)
NO (1) NO313517B1 (da)
NZ (1) NZ335733A (da)
OA (1) OA11123A (da)
PA (1) PA8442201A1 (da)
PE (1) PE46499A1 (da)
PL (1) PL333918A1 (da)
PT (1) PT946512E (da)
SI (1) SI0946512T1 (da)
SK (1) SK70899A3 (da)
TN (1) TNSN97198A1 (da)
TR (1) TR199901259T2 (da)
TW (1) TW491840B (da)
UA (1) UA59379C2 (da)
UY (1) UY24799A1 (da)
WO (1) WO1998024766A1 (da)
YU (1) YU25399A (da)
ZA (1) ZA9710906B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0891332T3 (da) * 1996-03-29 2004-07-05 Pfizer 6-phenylpyridyl-2-aminderivater
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
HN1998000125A (es) * 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados
FR2791674A1 (fr) * 1999-04-02 2000-10-06 Sod Conseils Rech Applic Nouveaux derives de 2-aminopyridines, leur utilisation en tant que medicaments et compositions pharmaceutiques les contenant
FR2780971B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Nouveaux derives de 2-aminopyridines, leur application en tant que medicaments et compositions pharmaceutiques les contenant
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
KR20010085364A (ko) * 1998-08-11 2001-09-07 데이비드 존 우드 Ｎｏｓ 억제제에 대한 신규 제약 용도
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SK12022001A3 (sk) 1999-02-25 2002-07-02 Pfizer Products Inc. 2-aminopyridíny obsahujúce ako substituenty kondenzované kruhové skupiny
MXPA01013452A (es) * 1999-07-23 2002-07-02 Shionogi & Co Inhibodores de diferenciacion th2.
FR2804429B1 (fr) * 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002080853A2 (en) * 2001-04-09 2002-10-17 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
CA2522323C (en) * 2003-04-14 2009-09-15 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
CN1295216C (zh) * 2003-07-04 2007-01-17 中国人民解放军军事医学科学院毒物药物研究所 吲哚酮类衍生物及其用于制备抗肿瘤药物的用途
SG160342A1 (en) * 2005-02-21 2010-04-29 Proximagen Ltd Inhibition or treatment of dyskinesia
WO2006105795A1 (en) * 2005-04-08 2006-10-12 Leo Pharma A/S Novel indolinone derivatives
WO2008021849A2 (en) * 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
RU2470017C2 (ru) 2007-06-08 2012-12-20 Янссен Фармацевтика Н.В. Производные пиперидина/пиперазина
AU2008258549B2 (en) 2007-06-08 2013-11-14 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JP5464709B2 (ja) 2007-06-08 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
CA2725933C (en) 2008-06-05 2018-01-16 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2404902A1 (en) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism
US11013844B2 (en) * 2014-11-20 2021-05-25 City Of Hope Treatment device for plasma virus inactivation
EP4063360A1 (en) * 2016-08-12 2022-09-28 Athenex, Inc. Biaryl compositions and methods for modulating a kinase cascade
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
PL3697785T3 (pl) 2017-10-18 2023-08-07 Jubilant Epipad LLC Związki imidazopirydynowe jako inhibitory pad
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
MX2020005363A (es) 2017-11-24 2020-10-01 Jubilant Episcribe Llc Compuestos heterociclicos como inhibidores de prmt5.
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
US20220267269A1 (en) * 2019-06-14 2022-08-25 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)
US12115154B2 (en) * 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014780A1 (en) 1991-02-19 1992-09-03 Akzo N.V. Stabilized carbon monoxide-olefin copolymers
WO1994014780A1 (en) * 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5621004A (en) 1994-06-03 1997-04-15 Robert W. Dunn Method for treating emesis
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
DK0891332T3 (da) * 1996-03-29 2004-07-05 Pfizer 6-phenylpyridyl-2-aminderivater
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

Also Published As

Publication number Publication date
US20020103227A1 (en) 2002-08-01
NZ335733A (en) 2001-01-26
CN1117077C (zh) 2003-08-06
PA8442201A1 (es) 2000-05-24
EP0946512B1 (en) 2003-10-08
UY24799A1 (es) 2001-08-27
JP2000505814A (ja) 2000-05-16
EA002907B1 (ru) 2002-10-31
PL333918A1 (en) 2000-01-31
CA2273479A1 (en) 1998-06-11
PT946512E (pt) 2004-01-30
AP848A (en) 2000-06-09
JP2005170924A (ja) 2005-06-30
IS5053A (is) 1999-05-18
CN1239952A (zh) 1999-12-29
ZA9710906B (en) 1999-06-09
YU25399A (sh) 2001-07-10
JP3604399B2 (ja) 2004-12-22
NO992725D0 (no) 1999-06-04
BR9714381A (pt) 2000-05-02
TR199901259T2 (xx) 1999-08-23
HUP0001848A2 (hu) 2001-04-28
HUP0001848A3 (en) 2002-03-28
EA199900448A1 (ru) 2000-02-28
DZ2361A1 (fr) 2002-12-28
ES2206691T3 (es) 2004-05-16
WO1998024766A1 (en) 1998-06-11
DE69725465D1 (de) 2003-11-13
CZ293863B6 (cs) 2004-08-18
KR100360633B1 (ko) 2002-11-13
MA26453A1 (fr) 2004-12-20
TNSN97198A1 (fr) 2005-03-15
US6235750B1 (en) 2001-05-22
ID19056A (id) 1998-06-11
US20020032191A1 (en) 2002-03-14
HN1997000149A (es) 1997-12-26
SK70899A3 (en) 2002-04-04
AU4791797A (en) 1998-06-29
BG103540A (bg) 2000-12-29
HN1997000027A (es) 1997-06-05
AR010331A1 (es) 2000-06-07
TW491840B (en) 2002-06-21
DE69725465T2 (de) 2004-05-06
AU766080B2 (en) 2003-10-09
PE46499A1 (es) 1999-05-12
CA2273479C (en) 2006-02-07
NO313517B1 (no) 2002-10-14
EP0946512A1 (en) 1999-10-06
KR20000057413A (ko) 2000-09-15
NO992725L (no) 1999-06-04
CZ201799A3 (cs) 2000-07-12
UA59379C2 (uk) 2003-09-15
SI0946512T1 (en) 2004-04-30
ATE251612T1 (de) 2003-10-15
AU7205001A (en) 2001-11-15
OA11123A (en) 2003-04-07
AP9701156A0 (en) 1998-01-31
IL130111A0 (en) 2000-06-01
HRP970664A2 (en) 1998-10-31

Similar Documents

Publication Publication Date Title
DK0946512T3 (da) 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO986090D0 (no) Fenylalaninderivater som integrininhibitorer
DK0818448T3 (da) Cycloalkanopyridiner som CETP-inhibitorer
DK0912518T3 (da) Substituerede pyridiner som selektive cyclooxygenase-2 inhibitorer
DK1114032T3 (da) 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
NO992821D0 (no) Ketobenzamider som calpain-inhibitorer
NO983669D0 (no) Coralyne analoger som topoisomeraseinhibitorer
EE9800219A (xx) Uued 19-nor-pregneeni derivaadid
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
DK1097127T3 (da) Diacylhydrazinderivater som integrininhibitorer
NO991384D0 (no) Substituerte heterocykler som anti-tumormidler
NO20021407D0 (no) Bifenylderivater anvendt som NHE-3-inhibitorer
NO996115L (no) Azetidinylpropylpiperidin-derivater, intermediater og anvendelse som tachykinin-antagonister
NO991560D0 (no) PDE IV som inhiberer 2-cyanoiminoimidazol-derivater
DK0922050T3 (da) 3-Descladinose-2,3-anhydroerythromycin-derivater
NO20010331D0 (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO991316D0 (no) 3-mercaptoacetylamino-1,5-substituerte-2-okso-azepanderivater som er anvendbare som inhibitorer av matriksmetalloproteinase
NO991994L (no) Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriksmetalloproteaseinhibitorer
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
NO20000094D0 (no) 6-Azaurcilderivater som IL-5 inhibitorer
NO983656D0 (no) Heterocyklyl-ergolinderivater som 5-HT1A reseptorligander